Yaron Shlomit, Yechezkel Matan, Yamin Dan, Razi Talish, Borochov Ilya, Shmueli Erez, Arbel Ronen, Netzer Doron
Schneider Children's Hospital, Petach Tikva, Israel.
Community Medical Services Division, Clalit Health Services, Tel-Aviv, Israel.
NPJ Vaccines. 2025 Jan 9;10(1):3. doi: 10.1038/s41541-025-01065-5.
Evidence regarding the high-dose (HD) vaccine's relative vaccine effectiveness (rVE) and absolute benefit in reducing influenza-related hospitalizations compared to the standard-dose (SD) vaccine is warranted. We estimated the adjusted rVE and the number needed to vaccinate (NNV) of the HD vaccine compared to the SD vaccine among Clalit Health Services members aged ≥65 years. Among 418,603 and 393,125 members vaccinated in the 2022-2023 and 2023-2024 influenza seasons, the adjusted rVE was 27% (95% CI: -12% to 61%) for 2022-2023 and 7% (95% CI: -36% to 42%) for 2023-2024, with NNV to prevent one hospitalization event being 2262 (95% CI: 1004 to ∞) and 7662 (95% CI: 1293 to ∞), respectively. Even among the highest-risk subgroup, the NNV was 1289 (95% CI: 571 to ∞) for 2022-2023 and 4719 (95% CI: 797 to ∞) for 2023-2024. The HD vaccine exhibited a limited incremental benefit, even for individuals at the highest risk.
关于高剂量（HD）疫苗与标准剂量（SD）疫苗相比在降低流感相关住院率方面的相对疫苗效力（rVE）和绝对益处的证据是有必要的。我们估计了Clalit医疗服务机构中年龄≥65岁成员中HD疫苗与SD疫苗相比的调整后rVE和疫苗接种所需人数（NNV）。在2022 - 2023年和2023 - 2024年流感季节接种疫苗的418,603名和393,125名成员中，2022 - 2023年的调整后rVE为27%（95%CI：-12%至61%），2023 - 2024年为7%（95%CI：-36%至42%），预防一次住院事件的NNV分别为2262（95%CI：1004至∞）和7662（95%CI：1293至∞）。即使在最高风险亚组中，2022 - 2023年的NNV为1289（95%CI：571至∞），2023 - 2024年为4719（95%CI：797至∞）。即使对于风险最高的个体，HD疫苗的增量益处也有限。
